David Devos
CHU de Lille · University Hospital, Lille · Hospitalier Régional Universitaire de Lille
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Devos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:03 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07074002 · Proof of Concept Study on BP1.4979 Effect on Essential TremorBioprojet · recruiting · Essential Tremor · principal investigator
- Ph1/Ph2NCT04332276 · Dopaminergic restauratIon by intraVEntriculaire AdministrationUniversity Hospital, Lille · completed · Parkinson Disease · study chair
- N/ANCT04179695 · Evaluation of a New Communication Aid Tool to Favor Global Patient Centered CareUniversity Hospital, Lille · recruiting · Parkinson's Disease · principal investigator
- Ph2/Ph3NCT03293069 · Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisUniversity Hospital, Lille · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2NCT03280251 · Methylphenidate and Cognitive Training in ElderlyUniversity Hospital, Lille · completed · Healthy Volunteers · principal investigator
- N/ANCT02883712 · Study of Predictors of Response to Anti Epilepsy in EpilepsyUniversity Hospital, Lille · terminated · Seizure · principal investigator
- N/ANCT02880033 · Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesUniversity Hospital, Lille · completed · Parkinson's Disease, Amyotrophic Lateral Sclerosis, Oxidative Stress · principal investigator
- Ph2NCT02728843 · Study of Parkinson's Early Stage With DeferiproneApoPharma · completed · Parkinson's Disease · principal investigator
- Ph2NCT02655315 · Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseUniversity Hospital, Lille · completed · Parkinson Disease · study chair
- N/ANCT02360891 · Study of Predictive Factors of Progression of Motor Neurone DiseaseUniversity Hospital, Lille · completed · Amyotrophic Lateral Sclerosis, Motor Neuron Disease · study chair
- N/ANCT02360683 · Predictive Factors and Subthalamic Stimulation in Parkinson's DiseaseUniversity Hospital, Lille · completed · Parkinson's Disease · study chair
- Ph4NCT01108029 · Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's DiseaseUniversity Hospital, Lille · completed · Parkinson's Disease, Gait Disorders, Neurologic · principal investigator
- Ph2/Ph3NCT00943748 · Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseUniversity Hospital, Lille · completed · Parkinson's Disease · principal investigator
- Ph4NCT00914095 · Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)University Hospital, Lille · completed · Parkinson's Disease, Gait Disorders, Neurologic, Dementia · principal investigator
- Ph3NCT00767091 · Study of Rivastigmine to Treat Parkinsonian Apathy Without DementiaUniversity Hospital, Lille · completed · Parkinson's Disease, Apathy, no Dementia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:03 UTC. The ranking covers the 200 most relevant of 40 PubMed records, and a shared surname and initials can bring in a namesake. All 40 on PubMed
- Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Antioxid Redox Signal · 2014523 citationsRCR 18.1
- Trial of Lixisenatide in Early Parkinson's Disease.N Engl J Med · 2024307 citationsRCR 49.9
- Trial of Deferiprone in Parkinson's Disease.N Engl J Med · 2022228 citationsRCR 20.0
- Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.Mov Disord · 2008185 citationsRCR 6.2
- 141 citationsRCR 5.3
- Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.J Neurol Neurosurg Psychiatry · 2014128 citationsRCR 5.5
- 113 citationsRCR 5.3
- Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.J Neurol Neurosurg Psychiatry · 2007107 citationsRCR 3.4
- Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?Antioxid Redox Signal · 2018100 citationsRCR 4.1
- Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.JAMA Neurol · 202591 citationsRCR 28.6